Novel pyrazolo[1,5-a]pyridines as p110I+/--selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR

• Published in: Bioorganic & medicinal chemistry Vol. 20; no. 1; pp. 58 - 68
• Main Authors: Kendall, Jackie D, Giddens, Anna C, Tsang, Kit Yee, Frederick, Raphaeel, Marshall, Elaine S, Singh, Ripudaman, Lill, Claire L, Lee, Woo-Jeong, Kolekar, Sharada, Chao, Mindy, Malik, Alisha, Yu, Shuqiao, Chaussade, Claire, Buchanan, Christina, Rewcastle, Gordon W, Baguley, Bruce C, Flanagan, Jack U, Jamieson, Stephen MF, Denny, William A, Shepherd, Peter R
• Format: Journal Article
• Language: English
• Published: 01-01-2012
• ISSN: 0968-0896
• DOI: 10.1016/j.bmc.2011.11.031

Structure-activity relationship studies of the pyrazolo[1,5-a]pyridine class of PI3 kinase inhibitors show that substitution off the hydrazone nitrogen and replacement of the sulfonyl both gave a loss of p110 alpha selectivity, with the exception of an N-hydroxyethyl analogue. Limited substitutions were tolerated around the phenyl ring; in particular the 2,5-substitution pattern was important for PI3 kinase activity. The N-hydroxyethyl compound also showed good inhibition of cell proliferation and inhibition of phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity. It had suitable pharmacokinetics for evaluation in vivo, and showed tumour growth inhibition in two human tumour cell lines in xenograft studies. This work has provided suggestions for the design of more soluble analogues.